Amarin Corp Plc (AMRN)

[HDGabor]

K-

So. what's the problem? R-IT will be stopped if

based on the design of REDUCE-IT, given the high thresholds of overwhelming efficacy and safety, and the robustness and consistency typically required to be achieved across key secondary endpoints and patient subgroups prior to an independent DMC recommending an early stop

It will be "knock it out of the park".
- efficacy: overwhelming
- key secondary endpoints: robustness and consistency
- key patient subgroups: robustness and consistency

Nobody said that it will be stopped based on data that are relatively insubstantial.

And once again: number of patient years is a nice marketing tool, but isn't relevant for RRR, statistical significance or any result ... Capice? Subscribe to one more course ...

Best,
G